Skip to content
Study details
Enrolling now

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

AstraZeneca
NCT IDNCT06023589ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

231

Study length

about 7 years

Ages

5–11

Locations

30 sites in AL, AR, AZ +12

About this study

This trial is testing a treatment called tezepelumab compared to a placebo (inactive pill) in children with severe asthma. The goal is to see if tezepelumab helps improve asthma control and is safe for this age group.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Receive Tezepelumab
PhasePhase 3
DrugTezepelumab

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

tezepelumab

Endpoints

Secondary: Change from baseline in Asthma Control Questionnaire - Interviewer Administered (ACQ-IA) score, Change from baseline in Paediatric Asthma Quality of Life Questionnaire (PAQLQ-(S)-IA) total score, Change from baseline in blood eosinophil count, Change from baseline in fractional exhaled nitric oxide (FeNO), Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1) percent predicted normal (PN), Change from baseline in pre-bronchodilator (pre-BD) peak expiratory flow (PEF), Change from baseline in total serum IgE, Change from baseline in weekly mean daily Paediatric Asthma Symptom Observer (PASO) score

Body systems

Respiratory